News >

Ongoing Research Builds Upon Advances in Stage III NSCLC, ALK+ Disease

Brandon Scalea
Published: Saturday, Apr 27, 2019

Ronan J. Kelly, MD, MBA

Ronan J. Kelly, MD, MBA

Although the PACIFIC trial introduced a new standard of care in the treatment of patients with inoperable stage III non–small cell lung cancer (NSCLC) by administering durvalumab (Imfinzi) post chemoradiotherapy, investigators are now trying to determine whether the combination of durvalumab plus chemoradiotherapy concurrently is safe and effective, said Ronan J. Kelly, MD, MBA.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Publication Bottom Border
Border Publication